Publicaciones en las que colabora con Antoni Bayes Genis (19)

2024

  1. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure

    Scientific Reports, Vol. 14, Núm. 1

  2. Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure

    CardioRenal Medicine, Vol. 14, Núm. 1, pp. 261-269

2023

  1. Assessment of filling pressures and fluid overload in heart failure: an updated perspective

    Revista Espanola de Cardiologia, Vol. 76, Núm. 1, pp. 47-57

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  4. Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure

    Revista Espanola de Cardiologia, Vol. 76, Núm. 2, pp. 121-123

  5. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  6. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

2022

  1. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

  2. Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

    CardioRenal Medicine, Vol. 12, Núm. 4, pp. 179-188

  3. Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure

    Revista Espanola de Cardiologia

  4. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  5. The “FIFTY SHADOWS” of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease

    Journal of Clinical Medicine, Vol. 11, Núm. 14

2021

  1. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 5, pp. 475-483

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 9, Núm. 4

  3. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 3792-3800

2018

  1. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

    Clinical Cardiology, Vol. 41, Núm. 4, pp. 476-480

  2. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

    Circulation, Vol. 137, Núm. 13, pp. 1320-1330